A recent prospective study with a longer follow-up (median 5 years) demonstrated that TNFα-i therapy in RA patients is associated with a significant reduction of 39% in the risk of myocardial infarction in comparison to DMARD therapy (50). The gene discussed is TNF; the disease is rheumatoid arthritis.